Some badly-needed good news for Sirtex Medical Limited shareholders

The science update released to the market this morning has some positives for Sirtex Medical Limited (ASX:SRX) shareholders.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After a raft of bad news in recent times that has knocked the share price down 38% in a year, Sirtex Medical Limited (ASX: SRX) shareholders may have cause for some optimism today.

After a follow-up analysis, the company found that its SIR-Spheres treatment combined with chemotherapy was significantly better than chemotherapy alone in a certain group of metastatic colorectal cancer (mCRC) patients.

Specifically, right-sided tumour sufferers (see image below) experienced a significant improvement in their outcomes when SIR-Spheres were added to their treatment regimen. It is hypothesised that SIR-Spheres are more effective because these patients traditionally have a poorer prognosis and inferior responses to treatment.

source: Company presentation

Unfortunately the SIR-Spheres were pretty much useless in left-sided tumour sufferers, but a future case might be made for including SIR-Spheres as standard treatment regime for right-sided tumours (which, ultimately, could result in a larger target market). From lemons, a few drops of lemonade:

"Treatment with… chemotherapy plus SIRT… in mCRC patients with primary tumours originating in the right colon results in a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy alone."

Unfortunately, and this is one of the most frustrating parts of scientific research:

"The drivers of the observed side-based differences in treatment impact remain to be elucidated."

Which is scientist-speak for 'we're not really sure why we got this result.' In my view the results are a positive but unlikely to be important to the company's sales and prospects in the near term. Rather, they suggest that Sirtex can potentially still expand into other treatment opportunities over the medium term.

In the near term, the new CEO's strategies to cut costs and focus on growing sales will be far more important. While I'm optimistic about the new strategy, I'll be waiting for evidence before making an investment decision either way on Sirtex.

Motley Fool contributor Sean O'Neill owns shares of Sirtex Medical Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

A white and black robot in the form of a human being stands in front of a green graphic holding a laptop and discussing robotics and automation ASX shares
Technology Shares

Joining the revolution: How I'd invest in ASX AI shares right now

Advances in artificial intelligence (AI) could usher in a new industrial revolution. Here’s how you can invest in it.

Read more »

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »